comparemela.com

Latest Breaking News On - கேம்பிரிட்ஜ் ஒன்றுபட்டது கிஂக்டம் - Page 5 : comparemela.com

Technology companies leaping ahead in DevOps, but Redgate survey shows challenges remain

Technology companies leaping ahead in DevOps, but Redgate survey shows challenges remain Media Links Cambridge UK, Tuesday 25 May – Having the highest DevOps adoption of all industry sectors, using more database types in development, and moving to the cloud faster are key factors in the strong business performance of the Technology sector over the last year. These are the highlights of a detailed examination of respondents from technology businesses and organizations to the latest State of Database DevOps survey from Redgate Software. The high number of respondents to the survey – over 3,000 IT professionals took part in this, it’s fifth year – provides an opportunity to uncover insights at a sector level and compare those to the average across all businesses and organizations.

HitGen : Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

Message : Required fields Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc. (“Dorian”), a private biotechnology company developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets that are of interest to Dorian. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Dorian. HitGen is a world leader in the development of the DEL technology and applications to early-stage small molecule drug discovery. The availability of over 1 trillion small molecules generated by the DEL technology and the efficiency of the screening process have made it possible for HitGen to enable drug discove

PervasID Wins with Queen s Award for Enterprise for Innovation 2021

PervasID Wins with Queen s Award for Enterprise for Innovation 2021 Media Cambridge-Based Battery-Free RFID Technology Innovator Used in Healthcare, Retail and Manufacturing Recognised with Prestigious Honour Cambridge, UK 29th April 2021 – PervasID, the company developing best-in-class battery-free Radio Frequency IDentification (RFID) reader systems for automating inventory and asset tracking, today announced that it has been honoured with a Queen’s Award for Enterprise for Innovation 2021. The award recognises PervasID’s pioneering work in battery-free tag tracking technology to allow enterprises to improve how they manage inventory and optimise their asset management. Now in its 55th year, the Queen’s Awards for Enterprise are the most prestigious business awards in the country, with winning businesses able to use the esteemed Queen’s Awards emblem for the next five years. PervasID now joins just over 7,000 UK enterprises which have received this Royal recognition si

BiologIC Technologies Helps Implement High-throughput Heat Inactivation of Patient Samples at Cambridge Lighthouse Laboratory

BiologIC Technologies Helps Implement High-throughput Heat Inactivation of Patient Samples at Cambridge Lighthouse Laboratory BiologIC Technologies, a pioneer in Industry 4.0 technologies for the bio-revolution, has collaborated with AstraZeneca and Electrolux Professional to implement a high-throughput solution for heat inactivation of patient samples at the Cambridge Lighthouse Laboratory. This solution renders the virus non-infectious, enhancing the safety, sustainability and scalability of the testing process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005091/en/ BiologIC Technologies helps implement high-throughput heat inactivation of patient samples at Cambridge UK COVID-19 Test Centre. (Photo: Business Wire) The Cambridge Lighthouse Laboratory, established by AstraZeneca, the University of Cambridge and GlaxoSmithKline, and subsequently partnering with Charles River Laboratories,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.